Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Thyroid Neoplasms 4Thyroid Cancer, Papillary 3Adenocarcinoma, Follicular 3Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 13Etoposide 10Prednisone 8Doxorubicin 8Whole-Body Irradiation 7Vincristine 7Rituximab 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Brentuximab Vedotin 7romidepsin 6fludarabine phosphate 6Mycophenolic Acid 6fludarabine 5Lenalidomide 5Gemcitabine 5Cytarabine 510-propargyl-10-deazaaminopterin 5Tacrolimus 4Granulocyte Colony-Stimulating Factor 4Carmustine 4Busulfan 4Antilymphocyte Serum 4pembrolizumab 3etoposide phosphate 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3Sirolimus 3Nivolumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell × Iodine-131 × Clear all
NCT00860171 2020-04-03

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Terminated
16 enrolled 10 charts
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡